Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes
Public ClinicalTrials.gov record NCT01011868. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group, Safety and Efficacy Study of BI 10773 (10 mg and 25 mg) Administered Orally, Once Daily Over 78 Weeks in Type 2 Diabetic Patients Receiving Treatment With Basal Insulin (Glargine, Detemir, or NPH Insulin Only) With or Without Concomitant Metformin and/or Sulfonylurea Therapy and Insufficient Glycemic Control
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 10773 at two different doses compared to placebo during long term treatment (78 weeks) in combination with basal insulin in patients with type 2 diabetes mellitus with insufficient glycaemic control.
Study identification
- NCT ID
- NCT01011868
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 494 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2009 (Type not available)
- Primary completion
- May 2012 (Actual)
- Completion
- Not listed
- Last update posted
- Sep 30, 2014
Started 2009
United States locations
- U.S. sites
- 56
- U.S. states
- 26
- U.S. cities
- 53
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1245.33.01014 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 1245.33.01047 Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| 1245.33.01060 Boehringer Ingelheim Investigational Site | Fresno | California | — | — |
| 1245.33.01013 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 1245.33.01008 Boehringer Ingelheim Investigational Site | Los Gatos | California | — | — |
| 1245.33.01019 Boehringer Ingelheim Investigational Site | National City | California | — | — |
| 1245.33.01055 Boehringer Ingelheim Investigational Site | Paramount | California | — | — |
| 1245.33.01012 Boehringer Ingelheim Investigational Site | Santa Ana | California | — | — |
| 1245.33.01054 Boehringer Ingelheim Investigational Site | Denver | Colorado | — | — |
| 1245.33.01046 Boehringer Ingelheim Investigational Site | Bradednton | Florida | — | — |
| 1245.33.01050 Boehringer Ingelheim Investigational Site | Brooksville | Florida | — | — |
| 1245.33.01059 Boehringer Ingelheim Investigational Site | Chiefland | Florida | — | — |
| 1245.33.01028 Boehringer Ingelheim Investigational Site | Clearwater | Florida | — | — |
| 1245.33.01029 Boehringer Ingelheim Investigational Site | Fleming Island | Florida | — | — |
| 1245.33.01048 Boehringer Ingelheim Investigational Site | Hollywood | Florida | — | — |
| 1245.33.01033 Boehringer Ingelheim Investigational Site | New Port Richey | Florida | — | — |
| 1245.33.01027 Boehringer Ingelheim Investigational Site | Atlanta | Georgia | — | — |
| 1245.33.01040 Boehringer Ingelheim Investigational Site | Decatur | Georgia | — | — |
| 1245.33.01062 Boehringer Ingelheim Investigational Site | Lawrenceville | Georgia | — | — |
| 1245.33.01020 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 1245.33.01044 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 1245.33.01024 Boehringer Ingelheim Investigational Site | Des Moines | Iowa | — | — |
| 1245.33.01022 Boehringer Ingelheim Investigational Site | Saint Louis | Maryland | — | — |
| 1245.33.01056 Boehringer Ingelheim Investigational Site | Olive Branch | Mississippi | — | — |
| 1245.33.01032 Boehringer Ingelheim Investigational Site | Kansas City | Missouri | — | — |
| 1245.33.01017 Boehringer Ingelheim Investigational Site | Omaha | Nebraska | — | — |
| 1245.33.01043 Boehringer Ingelheim Investigational Site | Las Vegas | Nevada | — | — |
| 1245.33.01051 Boehringer Ingelheim Investigational Site | New Hartford | New York | — | — |
| 1245.33.01007 Boehringer Ingelheim Investigational Site | Greensboro | North Carolina | — | — |
| 1245.33.01003 Boehringer Ingelheim Investigational Site | Jacksonville | North Carolina | — | — |
| 1245.33.01016 Boehringer Ingelheim Investigational Site | Salisbury | North Carolina | — | — |
| 1245.33.01005 Boehringer Ingelheim Investigational Site | Statesville | North Carolina | — | — |
| 1245.33.01038 Boehringer Ingelheim Investigational Site | Wilmington | North Carolina | — | — |
| 1245.33.01026 Boehringer Ingelheim Investigational Site | Winston-Salem | North Carolina | — | — |
| 1245.33.01025 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 1245.33.01001 Boehringer Ingelheim Investigational Site | Columbus | Ohio | — | — |
| 1245.33.01031 Boehringer Ingelheim Investigational Site | Tulsa | Oklahoma | — | — |
| 1245.33.01045 Boehringer Ingelheim Investigational Site | Eugene | Oregon | — | — |
| 1245.33.01018 Boehringer Ingelheim Investigational Site | Altoona | Pennsylvania | — | — |
| 1245.33.01041 Boehringer Ingelheim Investigational Site | Carlisle | Pennsylvania | — | — |
| 1245.33.01042 Boehringer Ingelheim Investigational Site | Landsdale | Pennsylvania | — | — |
| 1245.33.01004 Boehringer Ingelheim Investigational Site | Greer | South Carolina | — | — |
| 1245.33.01036 Boehringer Ingelheim Investigational Site | Mt. Pleasant | South Carolina | — | — |
| 1245.33.01035 Boehringer Ingelheim Investigational Site | Seneca | South Carolina | — | — |
| 1245.33.01058 Boehringer Ingelheim Investigational Site | Kingsport | Tennessee | — | — |
| 1245.33.01037 Boehringer Ingelheim Investigational Site | Memphis | Tennessee | — | — |
| 1245.33.01023 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1245.33.01030 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1245.33.01006 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1245.33.01011 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1245.33.01002 Boehringer Ingelheim Investigational Site | Sugar Land | Texas | — | — |
| 1245.33.01049 Boehringer Ingelheim Investigational Site | Salt Lake City | Utah | — | — |
| 1245.33.01015 Boehringer Ingelheim Investigational Site | Norfolk | Virginia | — | — |
| 1245.33.01009 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| 1245.33.01010 Boehringer Ingelheim Investigational Site | Federal Way | Washington | — | — |
| 1245.33.01061 Boehringer Ingelheim Investigational Site | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 43 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01011868, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 30, 2014 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01011868 live on ClinicalTrials.gov.